Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for CureVac (CVAC) over the last 6 years, with Q3 2025 value amounting to -$361238.0.

  • CureVac's Gains from Investment Securities rose 4563.13% to -$361238.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$361238.0, marking a year-over-year decrease of 10779.88%. This contributed to the annual value of $41675.2 for FY2024, which is 9888.6% down from last year.
  • According to the latest figures from Q3 2025, CureVac's Gains from Investment Securities is -$361238.0, which was up 4563.13% from -$859157.3 recorded in Q2 2025.
  • CureVac's 5-year Gains from Investment Securities high stood at $402.0 million for Q4 2021, and its period low was -$3.2 million during Q3 2023.
  • In the last 5 years, CureVac's Gains from Investment Securities had a median value of -$193726.6 in 2022 and averaged $29.7 million.
  • In the last 5 years, CureVac's Gains from Investment Securities soared by 589034.26% in 2021 and then tumbled by 2312839.31% in 2024.
  • CureVac's Gains from Investment Securities (Quarter) stood at $402.0 million in 2021, then tumbled by 96.92% to $12.4 million in 2022, then plummeted by 44.0% to $6.9 million in 2023, then crashed by 57.42% to $3.0 million in 2024, then crashed by 112.24% to -$361238.0 in 2025.
  • Its last three reported values are -$361238.0 in Q3 2025, -$859157.3 for Q2 2025, and -$1.0 million during Q1 2025.